Open AccessMaraviroc Intensification of Stable Antiviral Therapy in HIV-1–Infected Patients With Poor Immune Restoration
Author(s) -
Lise Cuzin,
Selma Trabelsi,
Pierre Delobel,
C. Barbuat,
Jacques Reynes,
Clotilde Allavena,
Gilles Peytavin,
Jade Ghosn,
Caroline Lascoux-Combe,
Christina Psomas,
Pierre Corbeau,
Philippe Flandre
Publication year - 2012
Publication title -
journal of acquired immune deficiency syndromes
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.162
H-Index - 157
eISSN - 1944-7884
pISSN - 1525-4135
DOI - 10.1097/qai.0b013e318273015f
Subject(s) - maraviroc , cart , medicine , regimen , viral load , clinical endpoint , population , adverse effect , ccr5 receptor antagonist , tissue tropism , efavirenz , antiretroviral therapy , gastroenterology , human immunodeficiency virus (hiv) , surgery , immunology , immune system , tropism , clinical trial , virus , mechanical engineering , chemokine , environmental health , chemokine receptor , engineering
To address the ability of a 24-week Maraviroc (MVC) intensification of a stable antiretroviral therapy (cART) to significantly increase the CD4 cell count slope.